FeesSafety
Pluang+

Revolution Medicines' cancer drug Rasonque posts record $198M launch in five weeks.

Market News
20 Nov 2026, 22:36 WIB
The Motley Fool
View Source
Bullish
Revolution Medicines' cancer drug Rasonque posts record $198M launch in five weeks.

Revolution Medicines' pancreatic cancer drug Rasonque achieved a historic launch, generating $198 million in revenue within its first five weeks on the market. The drug outperformed standard chemotherapy in Phase 3 trials, doubling median survival rates for patients. With a market cap of $34.8 billion and expectations of $3 billion in revenue next year, the company’s valuation reflects strong growth potential. Expansion into Europe and other markets, plus a robust pipeline, support a positive outlook despite some risks.

As of Nov 21, 2026 03:51 WIB, Revolution Medicines Inc. (RVMD) trades at USD 161.94 on Pluang, showing a 1.57% increase in the last day. The stock's market capitalization on Pluang stands at $34.47 billion, closely aligning with the article's valuation. Trading volume reached 3,351,151 shares, with an equal split between buy and sell orders, reflecting balanced investor interest.

More News (RVMD)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App